Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 6/20 | 0.81 |
| ▸ | SERPINC1 | P01008 | 4/20 | 0.56 |
| ▸ | BDNF | P23560 | 3/20 | 0.44 |
| ▸ | PTN | P21246 | 2/20 | 0.44 |
| ▸ | MDK | P21741 | 2/20 | 0.44 |
| ▸ | CXCL12 | P48061 | 3/20 | 0.44 |
| ▸ | CCL2 | P13500 | 2/20 | 0.44 |
| ▸ | CXCL10 | P02778 | 1/20 | 0.44 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.44 |
| ▸ | CCL5 | P13501 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 2/20 | 0.43 |
| ▸ | FGF1 | P05230 | 3/20 | 0.42 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.41 |
| ▸ | FGF2 | P09038 | 1/20 | 0.40 |
| ▸ | BMP2 | P12643 | 2/20 | 0.39 |
| ▸ | VEGFA | P15692 | 2/20 | 0.39 |
| ▸ | SHH | Q15465 | 2/20 | 0.39 |
| ▸ | IFNG | P01579 | 1/20 | 0.39 |
| ▸ | PF4 | P02776 | 1/20 | 0.39 |
| ▸ | SELP | P16109 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10157440 | 1.00 | F10 (0.81) | F10SERPINC1BDNFPTNMDK | |
| SCHEMBL18883211 | 1.00 | F10 (0.81) | F10SERPINC1BDNFPTNMDK | |
| SCHEMBL14665995 | 1.00 | F10 (0.81) | F10SERPINC1BDNFPTNMDK | |
| SCHEMBL15199336 | 1.00 | F10 (0.81) | F10SERPINC1BDNFPTNMDK | |
| SCHEMBL13130300 | 0.98 | F10 (0.84) | F10SERPINC1BDNFPTNMDK | |
| SCHEMBL29308178 | 0.94 | F10 (0.79) | F10SERPINC1BDNFPTNMDK | |
| SCHEMBL24064572 | 0.93 | F10 (0.74) | F10SERPINC1BDNFPTNMDK | |
| SCHEMBL14252707 | 0.92 | F10 (0.70) | F10SERPINC1BDNFPTNMDK | |
| SCHEMBL14706300 | 0.92 | F10 (0.70) | F10SERPINC1BDNFPTNMDK | |
| SCHEMBL14666015 | 0.90 | F10 (0.68) | F10SERPINC1BDNFPTNMDK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036234-B2 | Heparin conjugated to collagen-binding peptides for targeting to biological and synthetic tissues | NORTHWESTERN UNIVERSITY (US) | 2024-07-16 | — | — | US | disclosed |
| US-11795320-B2 | Grafted polymer and use thereof | BAUSCH + LOMB IRELAND LIMITED (IE) | 2023-10-24 | — | — | US | disclosed |
| US-11325987-B2 | Solid state nanopores aided by machine learning for identification and quantification of heparins and glycosaminoglycans | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2022-05-10 | — | — | US | disclosed |
| US-20210369665-A1 | METHODS OF TREATING VIRAL INFECTION USING PROTEASE INHIBITORS | LOWELL THERAPEUTICS INC (US) | 2021-12-02 | — | — | US | disclosed |
| US-20210299158-A1 | Heparin Conjugated to Collagen-Binding Peptides for Targeting to Biological and Synthetic Tissues | NORTHWESTERN UNIVERSITY (US) | 2021-09-30 | — | — | US | disclosed |
| US-20190256616-A1 | SOLID STATE NANOPORES AIDED BY MACHINE LEARNING FOR IDENTIFICATION AND QUANTIFICATION OF HEPARINS AND GLYCOSAMINOGLYCANS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2019-08-22 | — | — | US | disclosed |
| CN-106032527-B | It is a kind of tolerance low-density without feeder layer human pluripotent stem cells culture medium | 广州市搏克肿瘤研究所 | 2019-08-13 | — | — | CN | disclosed |
| WO-2019075213-A1 | HEPARIN CONJUGATED TO COLLAGEN-BINDING PEPTIDES FOR TARGETING TO BIOLOGICAL AND SYNTHETIC TISSUES | NORTHWESTERN UNIVERSITY (US) | 2019-04-18 | — | — | WO | disclosed |
| CN-106032527-A | Low-density-tolerant feeder-layer-free human pluripotency stem cell culture medium | 广州市搏克肿瘤研究所 | 2016-10-19 | — | — | CN | disclosed |
| US-20130129632-A1 | Quantum dot materials, methods for making them, and uses thereof | DUKE UNIVERSITY | 2013-05-23 | — | — | US | disclosed |
| US-20130129632-A1 | Quantum dot materials, methods for making them, and uses thereof | DUKE UNIVERSITY | 2013-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210369665-A1 | METHODS OF TREATING VIRAL INFECTION USING PROTEASE INHIBITORS | SERPINB1, TMPRSS15, PRSS1 | F10 730/4885SERPINC1 22/4885BDNF 4738/4885 |
| US-20210299158-A1 | Heparin Conjugated to Collagen-Binding Peptides for Targeting to Biological and Synthetic Tissues | COL14A1, MATR3, COL2A1 | F10 209/4885SERPINC1 5/4885BDNF 1273/4885 |
| US-20130129632-A1 | Quantum dot materials, methods for making them, and uses thereof | CLN6, SOD3, SOD1 | F10 4821/4885SERPINC1 4191/4885BDNF 3216/4885 |
| US-12036234-B2 | Heparin conjugated to collagen-binding peptides for targeting to biological and synthetic tissues | COL14A1, MATR3, COL2A1 | F10 209/4885SERPINC1 5/4885BDNF 1273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.